143 related articles for article (PubMed ID: 12968840)
1. Antibiotic administration in an animal model of chronic peritoneal dialysate exposure.
Mortier S; De Vriese AS; Leyssens A; Vanacker NJ; Faict D; Cornelissen M; De Ridder L; Lameire NH
Perit Dial Int; 2003; 23(4):331-8. PubMed ID: 12968840
[TBL] [Abstract][Full Text] [Related]
2. The effects of heparin administration in an animal model of chronic peritoneal dialysate exposure.
De Vriese AS; Mortier S; Cornelissen M; Palmans E; Vanacker NJ; Leyssens A; Faict D; De Ridder L; Lameire NH
Perit Dial Int; 2002; 22(5):566-72. PubMed ID: 12455567
[TBL] [Abstract][Full Text] [Related]
3. Effects of inhibition of the polyol pathway during chronic peritoneal exposure to a dialysis solution.
van Westrhenen R; Aten J; Aberra M; Dragt CA; Deira G; Krediet RT
Perit Dial Int; 2005 Feb; 25 Suppl 3():S18-21. PubMed ID: 16048249
[TBL] [Abstract][Full Text] [Related]
4. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat.
Park SH; Lee EG; Kim IS; Kim YJ; Cho DK; Kim YL
Perit Dial Int; 2004; 24(2):115-22. PubMed ID: 15119632
[TBL] [Abstract][Full Text] [Related]
5. Alternating Mupirocin/Gentamicin is Associated with Increased Risk of Fungal Peritonitis as Compared with Gentamicin Alone - Results of a Randomized Open-Label Controlled Trial.
Wong PN; Tong GM; Wong YY; Lo KY; Chan SF; Lo MW; Lo KC; Ho LY; Tse CW; Mak SK; Wong AK
Perit Dial Int; 2016; 36(3):340-6. PubMed ID: 27044796
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of intraperitoneal gentamicin in peritoneal dialysis patients with peritonitis (GIPD study).
Varghese JM; Roberts JA; Wallis SC; Boots RJ; Healy H; Fassett RG; Lipman J; Ranganathan D
Clin J Am Soc Nephrol; 2012 Aug; 7(8):1249-56. PubMed ID: 22700884
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of intraperitoneal cefazolin and gentamicin in empiric therapy of peritonitis in continuous ambulatory peritoneal dialysis patients.
Tosukhowong T; Eiam-Ong S; Thamutok K; Wittayalertpanya S; Na Ayudhya DP
Perit Dial Int; 2001; 21(6):587-94. PubMed ID: 11783768
[TBL] [Abstract][Full Text] [Related]
8. New Insights into the Effects of Chronic Kidney Failure and Dialysate Exposure on the Peritoneum.
Vlahu CA; Aten J; de Graaff M; van Veen H; Everts V; de Waart DR; Struijk DG; Krediet RT
Perit Dial Int; 2016 11-12; 36(6):614-622. PubMed ID: 27147290
[TBL] [Abstract][Full Text] [Related]
9. Do topical antibiotics reduce exit site infection rates and peritonitis episodes in peritoneal dialysis patients? The Pan Thames Renal Audit.
Davenport A;
J Nephrol; 2012; 25(5):819-24. PubMed ID: 22241640
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronan prevents the decreased net ultrafiltration caused by increased peritoneal dialysate fill volume.
Wang T; Cheng HH; Heimbürger O; Waniewski J; Bergström J; Lindholm B
Kidney Int; 1998 Feb; 53(2):496-502. PubMed ID: 9461112
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal urokinase and oral rifampicin for persisting asymptomatic dialysate infection following acute coagulase-negative staphylococcus peritonitis.
Demoulin N; Goffin E
Perit Dial Int; 2009; 29(5):548-53. PubMed ID: 19776049
[TBL] [Abstract][Full Text] [Related]
12. Positive dialysate gram stain predicts outcome of empirical antibiotic therapy for peritoneal dialysis-associated peritonitis.
Lee CC; Sun CY; Chang KC; Wu MS
Ther Apher Dial; 2010 Apr; 14(2):201-8. PubMed ID: 20438543
[TBL] [Abstract][Full Text] [Related]
13. Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study.
Ranganathan D; Varghese JM; Fassett RG; Lipman J; D'Intini V; Healy H; Roberts JA
BMC Nephrol; 2009 Dec; 10():42. PubMed ID: 20003546
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor in dialysate in relation to intensity of peritoneal inflammation.
Pawlaczyk K; Polubinska A; Numata N; Nakayama M; Pecoits-Filho R; Czekalski S; Lindholm B; Breborowicz A
Int J Artif Organs; 2008 Jun; 31(6):535-44. PubMed ID: 18609506
[TBL] [Abstract][Full Text] [Related]
15. Comparison of gentamicin and mupirocin in the prevention of exit-site infection and peritonitis in peritoneal dialysis.
Mahaldar A; Weisz M; Kathuria P
Adv Perit Dial; 2009; 25():56-9. PubMed ID: 19886318
[TBL] [Abstract][Full Text] [Related]
16. By reducing production of vascular endothelial growth factor octreotide improves the peritoneal vascular alterations induced by hypertonic peritoneal dialysis solution.
Günal AI; Celiker H; Akpolat N; Ustündag B; Duman S; Akcicek F
Perit Dial Int; 2002; 22(3):301-6. PubMed ID: 12227386
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal infusion of glucose-based dialysate in the rat--an animal model for the study of peritoneal advanced glycation end-products formation and effect on peritoneal transport.
Zeltzer E; Klein O; Rashid G; Katz D; Korzets Z; Bernheim J
Perit Dial Int; 2000; 20(6):656-61. PubMed ID: 11216555
[TBL] [Abstract][Full Text] [Related]
18. Icodextrin metabolism and alpha-amylase activity in nonuremic rats undergoing chronic peritoneal dialysis.
García-López E; Pawlaczyk K; Anderstam B; Qureshi AR; Kuzlan-Pawlaczyk M; Heimbürger O; Werynski A; Lindholm B
Perit Dial Int; 2007; 27(4):415-23. PubMed ID: 17602150
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis.
Roberts DM; Ranganathan D; Wallis SC; Varghese JM; Kark A; Lipman J; Roberts JA
Perit Dial Int; 2016; 36(4):415-20. PubMed ID: 26764340
[TBL] [Abstract][Full Text] [Related]
20. L-2-oxothiazolidine-4-carboxylate: an agent that modulates lipopolysaccharide-induced peritonitis in rats.
Korybalska K; Wieczorowska-Tobis K; Polubinska A; Wisniewska J; Moberly J; Martis L; Breborowicz A; Oreopoulos DG
Perit Dial Int; 2002; 22(3):293-300. PubMed ID: 12227385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
